GlassScriptPhysician profile
Veronica A Malone
NPI 1881995355
$6,960.48
in general payments reported to CMS, 2019-2025
43 companies · $922 in 2025
The $922 reported for 2025 was more than what 85% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $949 · 2022: $2,806 · 2023: $1,102 · 2024: $1,182 · 2025: $922.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,070 · Education: $135.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,070.49 |
| Education | $135.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Livanova USA, INC. | $1,683.29 | 2022 | |
| Abbvie INC. | $591.66 | 2021-2025 | |
| Ucb, INC. | $531.97 | 2021-2025 | Nayzilam, Fintepla, Briviact |
| Biogen, INC. | $408.89 | 2021-2025 | Vumerity, Tysabri |
| Emd Serono, INC. | $361.58 | 2021-2025 | Mavenclad, Mavenclad |
| Sk Life Science, INC. | $289.24 | 2021-2025 | Xcopri |
| Amneal Pharmaceuticals LLC | $249.85 | 2021-2025 | Rytary, Crexont, Ongentys 50mg Capsules 30 |
| Alexion Pharmaceuticals, INC. | $249.73 | 2021-2025 | Ultomiris |
| Upsher-Smith Laboratories LLC | $249.71 | 2021-2022 | |
| Neurocrine Biosciences, INC. | $216.74 | 2021-2024 | Ingrezza, Ongentys |
| Novartis Pharmaceuticals Corporation | $187.50 | 2021-2024 | |
| Teva Pharmaceuticals USA, INC. | $176.56 | 2021-2022 | |
| Lundbeck LLC | $155.10 | 2021-2025 | Rexulti, Vyepti |
| Immedica Pharma US, INC. | $129.29 | 2024 | |
| Genentech USA, INC. | $122.24 | 2023-2025 | Ocrevus Zunovo, Enspryng, Ocrevus |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Veronica Malone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.